Search results
Pfizer’s Phase III DMD gene therapy trial misses primary endpoint
Clinical Trials Arena via Yahoo Finance· 3 days agoDespite the...to moderate in severity, with serious adverse events linked to the treatment generally...
State-funded testing of COVID-19 treatment needs SC volunteers
South Carolina Daily Gazette via Yahoo News· 5 days agoCOLUMBIA – An international trio of chemists — two from Germany and one from the Czech Republic —...
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
Zacks via Yahoo Finance· 1 day agoFG-M701, a novel TL1A inhibitor, is in pre-clinical development. These next-generation IBD therapies...
Pfizer faces setback with gene therapy acquired from North Carolina firm - Triangle Business Journal
The Business Journals· 2 days agoPfizer is facing a major clinical setback in a gene therapy program with ties to the Triangle. The...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with...
Morningstar· 3 days agoPfizer Inc. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy ...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks· 3 days agoFree Report) announced that a phase III study on its mini-dystrophin gene therapy fordadistrogene movaparvovec for treating Duchenne muscular dystrophy (“DMD”) failed to meet the primary endpoint ...
Carpal Tunnel Syndrome: AAOS Updates Clinical Prac | Newswise
Newswise· 5 days agoROSEMONT, Ill. (June 11, 2024)—The American Academy of Orthopaedic Surgeons (AAOS) issued an update to the Clinical Practice Guideline (CPG) for Management of Carpal Tunnel ...
Can money conquer death? How wealthy people are trying to live forever
San Jose Mercury News· 15 hours agoPeter Diamandis, a week away from turning 63, bounds out of a Starbucks on a recent morning with a...